Diabetic 
Our understanding of its causation, however, is still incomplete. Nevertheless, recent biochemical advances seem promising and are very likely to influence our approach to the treatment of this condition.
Since there are many neuropathy syndromes associated with diabetes mellitus, it is more a ppropriate to speak of "dia betic neuropathies" rather than neuropathy. In considering the association of these two conditions, it should be recognized that the neuropathy may sometimes make its clinical appearance even before diabetes manifests itself. 1 This raises the question of whether neuropathy is a part of diabetes or a complication thereof.
There are many ways to classify diabetic Clinical Features IL is not our purpose to review the clinical features of all the the conditions mentioned above except to mention some of the less common or less well understood conditions. Numbness, neuritic pain and dysesthesias are easily recognized.
A mononeuropathic syndrome is frequently heralded by pain and paresthesia; the important thing lo remember is that the prognosis is uniformally good, although recovery may take two years or more. Thoracic neuropathy or radiculopathy' presents with acute chest pain or upper abdominal pain. Its early recognition may prevent an unneccssa ry s urgical procedure. Truncal polyneuropathy 6 and polyradi.culopathy 7 • 1 have also been described in ctiabetics.
Diabetic amyotrophy 9 is the term applied to the syndrome of acute onset of pain and weakness in one or both lower extremeties, especially the thigh muscles such as the quadriceps and psoas. Rapid wasting develops in the quadriceps and sometimes other muscles such as the glutei, hamstrings, etc. There is gradual recovery over a period of one to two years. The facts that (I) Hugh Garland described this syndrome first as ctiabetic myelopathy ,' 0 later corrected to amyotrophy, 11 and that (2) the clinical findings of these patients are not limited to the muscles supplied by the femoral nerves has resulted in multiple names. These include "symmetrical proximal motor neuropathies", 12 "femoral neuropathy", u elc. This also illustrates the difficulty in placing this syndrome in the usual classification. The exact pathology of this particular condition is not understood.
Diabetic neuropathic cachexia" is the conctition of diffuse motor neuropathy with generalized wasting of muscles and some pain. IL is generally considered a self-limited condition with good prognosis.
Pain in these patients may not necessarily be of neuropathic type, but may be due to degenerative arthrilis.
When sensory neuropathy has been present for a prolonged time, complications such as Charcot 's arthropathy, due to decreased nocifensive reflex, may develop.
Autonomic neuropathies are found in 20 to 400/o of diabetic patients if looked for carefully." Pupilary and sweating abnormalities are usually of no serious consequence other than the production of ArgyURobenson -like pupil, causing difficulties in differential diagnosis . Postural hypotension and .. silent" myocardial infarction" or arrythmias " are clearly worthy of attention. Nocturnal episodic diarrhea of the diabetics is known to respond to anPage 28 -JIMA: Volume 22, 1990 tibiotics'' and gastro -paresis is helped by metoclopramide. 19 Impotence is reported in as many as 500Jo of the ctiabetic male population. 2° For diagnosis and treatment, a very careful history, especially of erectile and ejaculatory functions, is essential.
Pathology and Pathogenesis
The diabetic changes observed in axons, myelin, and Schwann cells are nonspecific. There has been a debate over whether segmental demyelination or axonal degeneration is the primary event. More recently, electroneuromyographic studies have suggested that injury to the axon is the primary structure event. 21 The pathogenetic mechanisms that result from hyperglycemia have been studied for many decades. 22 For details, Low's description in "Muscle and Nerve" 2 J may be consulted. It may be useful at this juncture to recapitulate very briefly the anatomic physiology and biochemistry. A nerve fiber consists of three elements: a) Axon b) Myelin Sheath c) Schwann cells.
The myelin sheath is composed of fatty structures and some proteins. It is wrapped around the axon longitudinally in an "onion skin" fashion. One Schwann cell is located in each internode (the nodes of Ranvier divide the entire length of the fiber into many internodes of various lengths). Saltatory conduction of the nerve impulse depends upon the integrity of the myelin sheath. Axonal filaments have their own flow of nutritive materials running from the cell body to the termination of the axon.
The energy required to maintain the nerve conduction velocity (physiological measure of the integrity of nerve function) 24 depends upon the A TPase activity in the nerve fiber. Also, myoinositol, a glucose isomer, helps in electrolyte and aminoacid transport in the nerve fibers.
In normal glucose metabolism hexokinase activity is the major activity in the nerve fiber, whereas aldose-reductase activity of the polyol pathway has a minor role. In the diabetic nerves, however, due to sustained high levels of glucose, the hexokinase activity becomes saturated and aldose-reductase activity is increased. As seen in the equation below, aldosereductase converts glucose, in the presence of NADPH, into sorbital, which in turn is converted to fructose by debydrogenase.
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Thjs result in an accumulation o f sorbital and fructose, which in turn decreases myoinositol; hence, activity of sodium-potassium-A TPase is decreased. Required energy consumption in the nerve fiber is reduced with a resultant decrease in the nerve conduction velocity. ii Involvement of vasa nervorum due to diabetic microangiopathyu producing ishemia will decrease the turnover of myelin and slow down the axonal transport system . 16 It is conceivable that all these factors, singly or in combination, acting over a long period of time may result in structural damage to the nerves in diabetics.
Treatment
From the above description, it seems plausible that reducing the activity of aldose-reductase may improve or prevent neuropathy in diabetics. 11 During the last five years, various diabetic centers have attempted trials of aldose-reductase inhibitors, both experimentally and in patients with diabetic neuropathy. Although the results have not been uniformly impressive, this L ine of treatment a ppears to have clear promise for the control of diabetic ncuropathy in the future.
Treatment of painful neuropathy with drugs such as diphenyl hydamoin and carbamazepine is well established . Anti-depressive medications, such as amitriptyline a lone or in combination with a phenothiazine, have been used more recently for the control of pain. 28 • 29 As far as the use of narcotic analgesics is concerned, caution should be exercised as these conditions generally have good prognosis. We anxiously wait for the release of aldose-reductase inhibitors such as sorbinil or tolrestat for the treatment of diabeti.c neuropathy.
